Farkon kwayar halitta ta duniya don ciwon gwiwa osteoarthritis

A KYAUTA Kyauta 2 | eTurboNews | eTN
Avatar na Linda Hohnholz
Written by Linda Hohnholz

Juniper Biologics ta sanar a yau cewa ta sami haƙƙin lasisi don haɓakawa da kuma tallata TG-C LD (TissueGene-C ƙananan kashi) don maganin ciwon osteoarthritis na gwiwa.

Yarjejeniyar ba da lasisin dalar Amurka miliyan 600 wacce ta shafi Asiya Pasifik, Gabas ta Tsakiya da Afirka an rattaba hannu da ita tare da Kolon Life Science kuma ita ce siyan Juniper Biologics na biyu a cikin 'yan watanni. A ƙarƙashin sharuɗɗan haɗin gwiwar, Juniper Biologics za su ɗauki alhakin haɓakawa da tallata TG-C LD ga ƙwararrun likitoci da asibitoci a cikin waɗannan yankuna. Kolon Life Science zai zama alhakin tallafawa ci gaba da kuma samar da TG-C LD.

TG-C LD wani magani ne na binciken da ba na tiyata ba wanda aka yaba da shi azaman maganin ƙwayar cuta ta farko ta duniya don maganin osteoarthritis na gwiwa, [i] wanda shine mafi yawan nau'in arthritis.[ii] A cewar bincike, osteoarthritis. an kiyasta shi ne na goma sha ɗaya [1] da ke haifar da nakasa a duk duniya tare da kimanin majinyata miliyan 300 a Asiya Pacific da Gabas ta Tsakiya da Afirka kadai, suna fama da mummunan tasirin cutar haɗin gwiwa. Yana ɗaya daga cikin manyan buƙatun likita waɗanda ba a cika su ba tsakanin yanayin musculoskeletal tare da haɗarin da aka nuna don haɓaka da shekaru[iii].

Farko na farko-in-aji cell-cell-mediated genetherapy, TG-C LD yana hari gwiwa osteoarthritis ta hanyar allurar intra-articular guda ɗaya. Kolon TissueGene, mai lasisi don TG-C a Amurka (ba TG-C LD), ya riga ya kammala gwajin gwaji na lokaci na 2 a Amurka, tare da bayanan farko da ke nuna ci gaba da jin zafi da haɓaka motsi bayan allura guda ɗaya a ciki. haɗin gwiwa gwiwa, mai yiwuwa har zuwa shekaru 2. Gwajin gwaji na asibiti na 3 a cikin Amurka wanda ya ƙunshi marasa lafiya 1,020 a halin yanzu suna gudana don tabbatar da aminci da ingancin TG-C. Bugu da ƙari don tabbatar da ƙididdiga mai mahimmancin rage jin zafi da haɓaka aikin da aka lura daga gwajin gwajin gwaji na US Phase 2, an tsara gwaje-gwajen don nuna jinkirin ci gaba da cutar don cimma DMOAD (Cutar Gyara Osteoarthritis Drug).

Shugaban Juniper Biologics, Raman Singh, ya ce: "Koyaushe muna neman gano wuraren da za mu iya yin bambanci kuma TG-C LD tana ba da taimako mai mahimmanci ga masu ciwon osteoarthritis na gwiwa waɗanda in ba haka ba za su buƙaci tiyata ko wasu zaɓuɓɓukan magani. Mun himmatu wajen samar da sabbin magunguna don magance osteoarthritis na gwiwa ta hanyar sake farfado da guringuntsi kuma mun yi imanin wannan sabuwar hanyar bincike za ta kawo sauki ga miliyoyin marasa lafiya a fadin yankin.

"Muna farin cikin yin aiki tare da Juniper Biologics don samar da sababbin hanyoyin da marasa lafiya za su iya samun damar wannan sabuwar fasahar binciken kwayar halitta. Wannan zai zama ingantacciyar fasahar mu da ƙimar kasuwancinta, "in ji Woosok Lee Shugaban da Shugaba, Kolon Life Science. "Mun yi imanin marasa lafiya a Asiya Pasifik, Gabas ta Tsakiya da Afirka za su iya cin gajiyar TG-C LD yayin da muke fuskantar matsananciyar tabbatar da ita azaman zaɓin daidaitaccen magani na duniya."

Game da marubucin

Avatar na Linda Hohnholz

Linda Hohnholz

Edita a shugaba don eTurboNews bisa ga eTN HQ.

Labarai
Sanarwa na
bako
0 comments
Bayanin Cikin Lissafi
Duba duk maganganu
0
Za a son tunanin ku, don Allah sharhi.x
()
x
Share zuwa...